BIOMEA FUSION, INC. RECRUITING STUDIES: • COVALENT-112 – Type 1 Diabetes: COVALENT-112 is a Phase 2 trial designed to examine beta-cell function, insulin sensitivity, and both glucose and lipid metabolism in participants with T1D treated with BMF-219. The study will last around 1 year. Those meeting the eligibility [...]

Go to Top